A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis

NCT ID: NCT01253577

Last Updated: 2015-06-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

105 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-31

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and efficacy of the Propel mometasone furoate implant when used following Functional Endoscopic Sinus Surgery (FESS) in patients with Chronic Sinusitis (CS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to assess the safety and efficacy of the Propel mometasone furoate implant when used following Functional Endoscopic Sinus Surgery (FESS) in patients with Chronic Sinusitis (CS). The Propel implant is designed to provide a mechanical spacing function within the sinus anatomy to separate mucosal tissues, provide stabilization of the middle turbinate, and thereby prevent tissue adhesions from forming. The implant is coated with a small amount of mometasone furoate (a corticosteroid) in order to help minimize post surgical inflammation within the supported tissues.

The study utilizes an intra-patient control design to assess the safety and efficacy of the drug-coated implant compared to the non-drug coated implant that is identical in appearance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Sinusitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug Coated

Sinus stent coated with steroid

Group Type ACTIVE_COMPARATOR

Sinus Stent with drug coating

Intervention Type DEVICE

Sinus stent coated with 370 ug of the corticosteroid mometasone furoate

Non coated

Sinus stent without drug coating

Group Type PLACEBO_COMPARATOR

Non Coated Sinus Stent

Intervention Type DEVICE

Sinus stent (visually identical) without drug coating

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sinus Stent with drug coating

Sinus stent coated with 370 ug of the corticosteroid mometasone furoate

Intervention Type DEVICE

Non Coated Sinus Stent

Sinus stent (visually identical) without drug coating

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has bilateral chronic sinusitis confirmed by CT scan and defined as inflammation of the mucosa of the nose and paranasal sinuses of at least 8 consecutive weeks' duration.
* Patient is indicated for and has consented to FESS.
* FESS successfully completed without significant complication that in the opinion of the physician would confound study results and the patient's anatomy remains amenable to Sinus Stent placement.


* CS diagnosis confirmed and documented by CT Scan within 6 months of the procedure.
* Patient has minimum total CT score (Lund-Mackay method) of 6. • Patient has bilateral ethmoid sinus disease confirmed by CT.

Exclusion Criteria

* insulin dependent diabetics
* oral steroid dependent condition
* glaucoma, ocular hypertension, posterior subcapsular cataracts
* middle turbinate resection
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Intersect ENT

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bradley Marple, MD

Role: PRINCIPAL_INVESTIGATOR

University of Texas

Neil Bhattacharyya, MD

Role: PRINCIPAL_INVESTIGATOR

Brighan & Women's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Central California ENT

Fresno, California, United States

Site Status

Colorado ENT & Allergy

Colorado Springs, Colorado, United States

Site Status

Northwestern University

Chicago, Illinois, United States

Site Status

Northshore University Health System

Evanston, Illinois, United States

Site Status

Advanced ENT & Allergy

Louisville, Kentucky, United States

Site Status

Charlotte Eye, ENT Associates

Charlotte, North Carolina, United States

Site Status

Austin ENT Clinics

Austin, Texas, United States

Site Status

University of Texas SW Medical School

Dallas, Texas, United States

Site Status

University of Texas Medical School

Houston, Texas, United States

Site Status

Intermountain ENT

Salt Lake City, Utah, United States

Site Status

Eastern Virgina Medical School

Norfolk, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Han JK, Marple BF, Smith TL, Murr AH, Lanier BJ, Stambaugh JW, Mugglin AS. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. Int Forum Allergy Rhinol. 2012 Jul-Aug;2(4):271-9. doi: 10.1002/alr.21044. Epub 2012 May 1.

Reference Type RESULT
PMID: 22550039 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P500-1009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CST1-Guided Oral Glucocorticoids Management for CRSwNP
NCT05598411 NOT_YET_RECRUITING PHASE4